MetLife Investment Management, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$81,130
-16.3%
68,7540.0%0.00%0.0%
Q2 2023$96,943
-19.9%
68,754
+39.2%
0.00%0.0%
Q4 2021$120,979
+188.7%
49,379
+197.0%
0.00%
Q3 2021$41,900
-70.9%
16,627
-67.1%
0.00%
-100.0%
Q2 2021$144,09350,5590.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders